Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Endocrinology

Standard of Care: Hormone Replacement Therapy (HRT)

At a Glance

For 46,XX gonadal dysgenesis, hormone replacement therapy (HRT) typically begins at age 11 or 12 with a slowly increasing dose of estrogen to mimic natural puberty. Physiologic HRT, such as an estradiol patch, is recommended over birth control pills to maximize bone density and final height.

Because the body cannot produce its own sex hormones in 46,XX gonadal dysgenesis, doctors use Hormone Replacement Therapy (HRT) to provide what the ovaries cannot [1][2]. HRT is not just about starting a period; it is a critical tool for building a strong skeleton and supporting overall development [3][4].

The Goals of Therapy

The primary mission of HRT is to mimic the natural process of puberty as closely as possible [5][6]. This involves:

  • Physical Maturity: Developing secondary sexual characteristics, such as breast development and hair growth [7][2].
  • Organ Growth: Encouraging the uterus to grow from its “infantile” size to a mature size [5][8].
  • Bone Strength: Protecting the skeleton during the critical years when the body is meant to reach “peak bone mass” [3][9].

What to Expect Day-to-Day

Starting hormone therapy is a significant milestone. As you begin HRT, it is normal to notice physical and emotional changes. You might experience mild breast tenderness as tissue begins to grow, changes in your mood as your body adjusts to the hormones, and possibly some vaginal discharge. Eventually, once the second hormone (progesterone) is added to your routine, you will experience the start of a regular menstrual cycle. Knowing what to expect can help ease the transition.

Why “Physiologic” HRT Matters

You may be offered physiologic HRT (using hormones that are bioidentical to what the body makes) rather than standard Combined Oral Contraceptive Pills (COCPs), commonly known as birth control [10][11].

Feature Physiologic HRT (e.g., 17β-estradiol) Birth Control Pills (COCPs)
Hormone Type 17β-estradiol (identical to human estrogen) [12]. Ethinyl estradiol (a potent synthetic estrogen) [10].
Bone Health Shown to be more effective at improving bone density and structure [10][11]. May be less effective at supporting optimal bone accrual in teens [11].
Growth Impact Does not suppress IGF-1 (a growth-related hormone) [13]. Can lower IGF-1 levels, potentially affecting final height [13].
Delivery Often given via a transdermal patch (through the skin) [12][14]. Usually an oral pill [10].

The Timeline of Treatment

HRT typically begins around the age of 11 or 12, or as soon as the diagnosis is confirmed if the patient is older [3][4].

  1. The Estrogen Ramp-Up: Treatment often starts with a very low dose of estrogen [12][5]. Over 2 to 3 years, the dose is slowly increased (titrated) to allow for natural-looking breast development and gradual uterine growth [5][14].
  2. Adding Progesterone: After about two years of estrogen—or once breakthrough bleeding occurs—doctors add a second hormone called progesterone [6]. This protects the lining of the uterus and establishes a regular cycle [7][4].

Long-Term Bone Protection

In people with 46,XX gonadal dysgenesis, estrogen deficiency significantly increases the risk of osteoporosis (thin, brittle bones) [15][16]. Because bones continue to strengthen into early adulthood, continuing HRT until the typical age of menopause (around 50) is mandatory to prevent fractures and maintain metabolic health [15][16][17]. Consistent therapy ensures that the body remains supported throughout every stage of life [9][16].

Common questions in this guide

When does hormone replacement therapy start for 46,XX gonadal dysgenesis?
Treatment typically begins around age 11 or 12, or as soon as a diagnosis is made if the patient is older. It starts with a very low dose of estrogen that slowly increases over two to three years to allow for natural physical development.
Why is physiologic HRT recommended instead of standard birth control pills?
Physiologic HRT uses bioidentical hormones like 17β-estradiol, which are significantly better at improving bone density and structure than the synthetic estrogen found in standard birth control. It also avoids suppressing growth hormones, helping teens reach their full height.
When is progesterone added to my hormone therapy plan?
Progesterone is usually added after about two years of estrogen therapy, or whenever breakthrough bleeding occurs. This second hormone protects the lining of the uterus and establishes a regular menstrual cycle.
How long will I need to take hormone replacement therapy?
Patients must continue hormone therapy until the standard age of menopause, which is around 50 years old. Consistent, long-term treatment is mandatory to prevent osteoporosis and maintain your metabolic health.
What physical changes will I experience when starting HRT?
You can expect normal signs of puberty, including breast development, hair growth, and gradual growth of the uterus. You may also experience mild breast tenderness and temporary mood changes as your body adjusts to the hormones.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which type of estrogen will be used (e.g., transdermal patch or oral tablet), and is it 17β-estradiol?
  2. 2.Why is this specific HRT regimen better for my bone health than standard birth control pills?
  3. 3.What is the timeline for increasing my estrogen dose over the next few years?
  4. 4.At what point will we add progesterone to my treatment plan?
  5. 5.Should we schedule a baseline DEXA scan to check my bone density before starting therapy?
  6. 6.How often will we monitor my uterine growth and bone health during this process?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Misdiagnosis of associated mullerian agenesis in a female with 46, XX gonadal dysgenesis: a case report and review of literature.

    Opdecam L, Barudy Vasquez J, Camerlinck M, Makar A

    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 2021; (41(7)):1164-1165 doi:10.1080/01443615.2020.1798908.

    PMID: 33054466
  2. 2

    Clinical features and management of 33 patients with 46,XX pure gonadal dysgenesis.

    Huang H, Wang CQ, Tian QJ

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2016; (32(12)):995-998 doi:10.1080/09513590.2016.1190820.

    PMID: 27250571
  3. 3

    Impact of ovarian insufficiency on bone health in childhood cancer survivors: Two cases.

    He CY, Lee DJ, Foster KL, Gordon CM

    Bone 2024; (178()):116930 doi:10.1016/j.bone.2023.116930.

    PMID: 37844715
  4. 4

    The Care of Adolescents and Young Adults with Turner Syndrome: A Pediatric and Adolescent Gynecology Perspective.

    Dowlut-McElroy T, Shankar RK

    Journal of pediatric and adolescent gynecology 2022; (35(4)):429-434 doi:10.1016/j.jpag.2022.02.002.

    PMID: 35272055
  5. 5

    Sex hormone replacement therapy for individuals with Turner syndrome.

    Backeljauw P, Klein K

    American journal of medical genetics. Part C, Seminars in medical genetics 2019; (181(1)):13-17 doi:10.1002/ajmg.c.31685.

    PMID: 30809949
  6. 6

    Hypogonadism in male and female: which is the best treatment?

    Bertelli E, DI Frenna M, Cappa M, et al.

    Minerva pediatrics 2021; (73(6)):572-587 doi:10.23736/S2724-5276.21.06534-4.

    PMID: 34309345
  7. 7

    Pure 46, XY gonadal dysgenesis and 46, XY complete androgen insensitivity syndrome: A case report.

    Yu T, Liu L

    Medicine 2024; (103(25)):e38297 doi:10.1097/MD.0000000000038297.

    PMID: 38905377
  8. 8

    Misdiagnosis of Mullerian agenesis in a patient with 46, XX gonadal dysgenesis: a missed opportunity for prevention of osteoporosis.

    Thewjitcharoen Y, Veerasomboonsin V, Nakasatien S, et al.

    Endocrinology, diabetes & metabolism case reports 2019; (2019()).

    PMID: 31809259
  9. 9

    Impact of Hormonal Replacement Therapy on Bone Mineral Density in Premature Ovarian Insufficiency Patients.

    Podfigurna A, Maciejewska-Jeske M, Nadolna M, et al.

    Journal of clinical medicine 2020; (9(12)) doi:10.3390/jcm9123961.

    PMID: 33297406
  10. 10

    Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial.

    Ackerman KE, Singhal V, Baskaran C, et al.

    British journal of sports medicine 2019; (53(4)):229-236 doi:10.1136/bjsports-2018-099723.

    PMID: 30301734
  11. 11

    Effects of Estrogen Replacement on Bone Geometry and Microarchitecture in Adolescent and Young Adult Oligoamenorrheic Athletes: A Randomized Trial.

    Ackerman KE, Singhal V, Slattery M, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2020; (35(2)):248-260 doi:10.1002/jbmr.3887.

    PMID: 31603998
  12. 12

    Estrogen Replacement in Turner Syndrome: Literature Review and Practical Considerations.

    Klein KO, Rosenfield RL, Santen RJ, et al.

    The Journal of clinical endocrinology and metabolism 2018; (103(5)):1790-1803 doi:10.1210/jc.2017-02183.

    PMID: 29438552
  13. 13

    Impact of Route of Estrogen Administration on Bone Turnover Markers in Oligoamenorrheic Athletes and Its Mediators.

    Singhal V, Ackerman KE, Bose A, et al.

    The Journal of clinical endocrinology and metabolism 2019; (104(5)):1449-1458 doi:10.1210/jc.2018-02143.

    PMID: 30476179
  14. 14

    Current Recommended Estrogen Dosing for Pubertal Induction in Turner Syndrome Results in Normal Uterine Growth.

    Lindsay Mart F, Gutmark-Little I, Streich-Tilles T, et al.

    The Journal of clinical endocrinology and metabolism 2024; (109(3)):e1040-e1047 doi:10.1210/clinem/dgad649.

    PMID: 37933636
  15. 15

    Premature ovarian insufficiency: A hormonal treatment approach.

    Benetti-Pinto CL, Soares Júnior JM, Maciel GA, et al.

    Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia 2020; (42(8)):511-518 doi:10.1055/s-0040-1716929.

    PMID: 32898916
  16. 16

    Bone mineral density in patients with primary ovarian insufficiency: A systematic review and Meta-Analysis.

    Jiang M, Gao Y, Hou H, et al.

    European journal of obstetrics, gynecology, and reproductive biology 2024; (295()):219-227 doi:10.1016/j.ejogrb.2024.02.013.

    PMID: 38387304
  17. 17

    Hormone replacement therapy in young women with surgical primary ovarian insufficiency.

    Sarrel PM, Sullivan SD, Nelson LM

    Fertility and sterility 2016; (106(7)):1580-1587 doi:10.1016/j.fertnstert.2016.09.018.

    PMID: 27793381

This page provides educational information about hormone replacement therapy for 46,XX gonadal dysgenesis. Always consult your pediatric endocrinologist or gynecologist for personalized treatment and monitoring decisions.

Get notified when new evidence is published on 46,XX gonadal dysgenesis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.